Holen Sie sich die Stockscreener-App
37.19
0.81%
0.30
Handel nachbörslich:
37.19
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines director Weber resigns ahead of annual meeting - Investing.com
Revolution Medicines COO Horn sells $139k in stock - Investing.com
Revolution Medicines COO Horn sells $139k in stock By Investing.com - Investing.com UK
(RVMD) Proactive Strategies - news.stocktradersdaily.com
(RVMD) Investment Analysis - news.stocktradersdaily.com
rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.
Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance
Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace
Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus
When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com
Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus
Revolution Medicines begins phase 3 trial for lung cancer drug - Investing.com
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks
Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance
Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News
Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks
RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus
The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb
Oppenheimer Raises Price Target for RVMD, Maintains Outperform R - GuruFocus
RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus
Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Revolution Medicines Reports Q1 2025 Financial Results - TipRanks
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Reven - GuruFocus
Revolution Medicines (RVMD) Advances Key Clinical Trials and Str - GuruFocus
Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com
Revolution Medicines Q1 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines Q1 Net Loss Widens - marketscreener.com
Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Revenue of $0.00 Million, Missing Estimates - GuruFocus
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines patents new GTPase KRAS mutant inhibitors - BioWorld MedTech
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF), Encompass Health (EHC) and Revolution Medicines (RVMD) - The Globe and Mail
Revolution Medicines (RVMD) Reports Promising Data for Zoldonras - GuruFocus
A Guide To The Risks Of Investing In Revolution Medicines Inc (RVMD) - knoxdaily.com
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data - marketscreener.com
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):